Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Pandoraon Jul 01, 2024 10:56pm
121 Views
Post# 36113811

RE:RE:RE:RE:RE:RE:RE:New all time low at 0.04 cad?

RE:RE:RE:RE:RE:RE:RE:New all time low at 0.04 cad?
Just as a refresher  re my previous post:

It was in October 2021 that it was announced they were in discussions with a major company.

In December it was announced that they had hired Linda Pullan of Pullan Consulting to negotiate with this major cosmetic company.

It was in June of 2022 that it was announced that an agreement had been signed with Allergen Aesthetics, a division of Abbvie Pharmaceutical with an upfront payment and further payments on achievement of certain milestones. This was a momentous development for this small company!

We are now 2 years further down the road in June 2024 and what have we received -- particularly as shareholders? In June of 2022 the share price was sitting around the 20 cent mark. After the news came out the share price ran up to the 34 cent area.

Today we sit at 4.5 cents. What did Linda Pullan actually negotiate? Was her negotiation so great (or so bad) it would knock the sox off our share price? Was her compensation based on share price? I don't think so.
<< Previous
Bullboard Posts
Next >>